

---

---

**United States**  
**Securities and Exchange Commission**  
Washington, D.C. 20549

---

**Schedule 13G**  
(Rule 13d-102)

Information to be Included in Statements Filed Pursuant  
to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed  
Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 3)\*

---

**Corcept Therapeutics Incorporated**  
(Name of Issuer)

**Common Stock**  
(Title of Class of Securities)

218352102  
(CUSIP Number)

**December 31, 2023**  
(Date of Event Which Requires Filing of this Statement)

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

1	Names of Reporting Persons Joseph K. Belanoff	
2	Check the Appropriate Box if a Member of a Group (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC Use Only	
4	Citizenship or Place of Organization United States	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 6,581,918
	6	Shared Voting Power 0
	7	Sole Dispositive Power 6,581,918
	8	Shared Dispositive Power 0
9	Aggregate Amount Beneficially Owned by Each Reporting Person 6,581,918	
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable	
11	Percent of Class Represented by Amount in Row 9 6.1%	
12	Type of Reporting Person IN	

**ITEM 1.****(a) Name of Issuer:**

Corcept Therapeutics Incorporated (the "Issuer").

**(b) Address of Issuer's Principal Executive Offices:**

149 Commonwealth Drive  
Menlo Park, CA 94025

**ITEM 2.****(a) Name of Person Filing:**

This statement is filed on behalf of Dr. Joseph K. Belanoff (the "Reporting Person").

**(b) Address or Principal Business Office:**

The business address of the Reporting Person is c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, CA 94025.

**(c) Citizenship of each Reporting Person is:**

The Reporting Person is a citizen of the United States.

**(d) Title of Class of Securities:**

Common stock, par value \$0.001 per share ("Common Stock").

**(e) CUSIP Number:**

218352102

**ITEM 3.**

Not applicable.

**ITEM 4. Ownership.**

The ownership information below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2023, based upon 107,155,403 shares of Common Stock outstanding as of December 31, 2023.

**(a) Amount beneficially owned:**

The Reporting Person beneficially owns 6,581,918 shares of Common Stock, which consist of (i) 2,831,918 shares of Common Stock and (ii) 3,750,000 shares of Common Stock underlying stock options that are exercisable prior to March 1, 2024.

**(b) Percent of class: 6.1%****(c) Number of shares as to which the person has:**

- (i) Sole power to vote or to direct the vote: 6,581,918
- (ii) Shared power to vote or direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 6,581,918
- (iv) Shared power to dispose or to direct the disposition of: 0

**ITEM 5. Ownership of Five Percent or Less of a Class.**

Not applicable.

**ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

Not applicable.

**ITEM 8. Identification and Classification of Members of the Group.**

Not applicable.

**ITEM 9. Notice of Dissolution of Group.**

Not applicable.

**ITEM 10. Certification.**

Not applicable.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Date:** February 12, 2024

/s/ Joseph K. Belanoff